• norsk
    • English
  • norsk 
    • norsk
    • English
  • Logg inn
Vis innførsel 
  •   Hjem
  • Handelshøyskolen BI
  • Articles
  • Scientific articles
  • Vis innførsel
  •   Hjem
  • Handelshøyskolen BI
  • Articles
  • Scientific articles
  • Vis innførsel
JavaScript is disabled for your browser. Some features of this site may not work without it.

Should pharmaceutical costs be curbed?

Brekke, Kurt R.; Dalen, Dag Morten; Strøm, Steinar
Journal article, Peer reviewed
Thumbnail
Åpne
Dalen_NEPR_2012.pdf (439.6Kb)
Permanent lenke
http://hdl.handle.net/11250/93886
Utgivelsesdato
2012
Metadata
Vis full innførsel
Samlinger
  • Scientific articles [1667]
Originalversjon
http://dx.doi.org/10.6027/TN2013-514
Sammendrag
Pharmaceuticals account for almost a fifth of total health spending in

OECD-countries. Both pharmaceutical innovations and the aging of the

population explain the increasing importance of pharmaceuticals in health

care. Due to the importance of patent protection and insurance coverage,

pharmaceutical markets are subjected to economic regulation – both on

the supply-side and the demand-side. In this paper, we briefly review the

Nordic pharmaceutical market, before explaining the main regulatory

policy measures taken by governments in these countries. Empirical research

has been undertaken to investigate regulation and competition, and

we provide a review of some of the findings.
Beskrivelse
This is an Open Access journal. www.norden.org
Utgiver
Nordisk ministerråd
Tidsskrift
Nordic Economic Policy Review

Kontakt oss | Gi tilbakemelding

Personvernerklæring
DSpace software copyright © 2002-2019  DuraSpace

Levert av  Unit
 

 

Bla i

Hele arkivetDelarkiv og samlingerUtgivelsesdatoForfattereTitlerEmneordDokumenttyperTidsskrifterDenne samlingenUtgivelsesdatoForfattereTitlerEmneordDokumenttyperTidsskrifter

Min side

Logg inn

Statistikk

Besøksstatistikk

Kontakt oss | Gi tilbakemelding

Personvernerklæring
DSpace software copyright © 2002-2019  DuraSpace

Levert av  Unit